Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 17, 2007. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically regarding the SmithKline Beecham Bonus Investment Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a specific share transaction event.
- Transaction Price: GBP 13.70 per share.
- Transaction Type: Increase in interest in Ordinary Shares via dividend re-investment.
- Dividend Date: January 4, 2007.
Material Changes
The filing reports an increase in shareholdings for Mr. R Bondy and other participants in the SmithKline Beecham Bonus Investment Plan. This change resulted from the automatic re-investment of dividends paid on January 4, 2007, rather than a direct market purchase or a change in corporate financial performance.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is a regulatory disclosure of a specific insider transaction under Disclosure Rule 3.1.4R(1)(a).
Key Facts for Investor Verification
- Verify the total number of shares acquired by Mr. R Bondy and other plan participants, as the specific quantity is not explicitly detailed in the provided text snippet.
- Confirm the total dividend payout amount for the January 4, 2007 distribution to understand the scale of the re-investment.
- Check subsequent filings for any further changes in director shareholdings or related party transactions.